Tandem Historical Income Statement

TNDM Stock

USD 35.15 2.38 6.34%

Historical analysis of Tandem Diabetes income statement accounts such as Research Development of 204.9 M, Total Operating Expenses of 725.6 M, Total Other Income Expense Net of 12.3 M or Income Tax Expense of 2.2 M can show how well Tandem Diabetes Care performed in making a profits. Evaluating Tandem Diabetes income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Tandem Diabetes's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Tandem Diabetes Care latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Tandem Diabetes Care is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

About Tandem Income Statement Analysis

Tandem Diabetes Care Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Tandem Diabetes shareholders. The income statement also shows Tandem investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Tandem Diabetes Income Statement Chart

At this time, Tandem Diabetes' Income Tax Expense is very stable compared to the past year. As of the 18th of January 2025, Total Revenue is likely to grow to about 902.9 M, though Operating Income is likely to grow to (199.4 M).

Selling General Administrative Other Operating Expenses Operating Income Total Operating Expenses Total Other Income Expense Net

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Tandem Diabetes Care. It is also known as Tandem Diabetes overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Operating Income

Operating Income is the amount of profit realized from Tandem Diabetes Care operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Tandem Diabetes Care is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Tandem Diabetes' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Tandem Diabetes Care current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

	2023	2024	2025 (projected)
Interest Expense	9.9M	11.4M	6.0M
Depreciation And Amortization	15.7M	18.1M	19.0M

Interest Expense Depreciation And Amortization

Tandem Diabetes income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Total Revenue	Gross Profit	Cost Of Revenue	Net Income From Continuing Ops	Non Operating Income Net Other	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Extraordinary Items	Non Recurring
Depreciation And Amortization		0.55	0.99	0.98	-0.66	-0.65	0.96	-0.6	0.97	-0.64	0.28	-0.65	0.16	0.97	0.96	0.98	-0.51	0.15	0.72	0.75	0.73	0.88	-0.63	-0.63
Interest Expense	0.55		0.46	0.46	-0.47	-0.45	0.44	-0.43	0.47	-0.55	-0.16	-0.55	-0.1	0.43	0.4	0.45	-0.41	-0.25	0.15	0.35	0.16	0.48	-0.21	-0.21
Selling General Administrative	0.99	0.46		1.0	-0.68	-0.67	0.98	-0.62	0.99	-0.66	0.32	-0.66	0.21	0.99	0.98	0.99	-0.54	0.18	0.77	0.79	0.8	0.88	-0.65	-0.65
Other Operating Expenses	0.98	0.46	1.0		-0.7	-0.69	0.99	-0.64	1.0	-0.67	0.33	-0.68	0.23	0.98	0.97	0.99	-0.57	0.19	0.78	0.82	0.81	0.89	-0.66	-0.66
Operating Income	-0.66	-0.47	-0.68	-0.7		0.99	-0.76	0.99	-0.76	0.95	-0.45	0.96	-0.43	-0.56	-0.52	-0.61	0.93	-0.27	-0.84	-0.92	-0.86	-0.6	0.64	0.64
Ebit	-0.65	-0.45	-0.67	-0.69	0.99		-0.75	1.0	-0.74	0.96	-0.44	0.96	-0.44	-0.55	-0.5	-0.6	0.94	-0.28	-0.84	-0.9	-0.84	-0.59	0.61	0.61
Research Development	0.96	0.44	0.98	0.99	-0.76	-0.75		-0.71	1.0	-0.73	0.39	-0.73	0.3	0.96	0.94	0.97	-0.66	0.23	0.84	0.88	0.86	0.89	-0.7	-0.7
Ebitda	-0.6	-0.43	-0.62	-0.64	0.99	1.0	-0.71		-0.7	0.96	-0.44	0.96	-0.45	-0.5	-0.45	-0.54	0.95	-0.28	-0.83	-0.88	-0.82	-0.54	0.6	0.6
Total Operating Expenses	0.97	0.47	0.99	1.0	-0.76	-0.74	1.0	-0.7		-0.73	0.36	-0.73	0.26	0.96	0.95	0.98	-0.63	0.21	0.82	0.86	0.85	0.88	-0.7	-0.7
Income Before Tax	-0.64	-0.55	-0.66	-0.67	0.95	0.96	-0.73	0.96	-0.73		-0.18	1.0	-0.37	-0.55	-0.5	-0.59	0.95	-0.01	-0.78	-0.85	-0.78	-0.54	0.59	0.59
Total Other Income Expense Net	0.28	-0.16	0.32	0.33	-0.45	-0.44	0.39	-0.44	0.36	-0.18		-0.19	0.41	0.28	0.26	0.29	-0.26	0.97	0.51	0.49	0.5	0.42	-0.33	-0.33
Net Income	-0.65	-0.55	-0.66	-0.68	0.96	0.96	-0.73	0.96	-0.73	1.0	-0.19		-0.38	-0.55	-0.51	-0.59	0.95	-0.01	-0.79	-0.85	-0.79	-0.55	0.59	0.59
Income Tax Expense	0.16	-0.1	0.21	0.23	-0.43	-0.44	0.3	-0.45	0.26	-0.37	0.41	-0.38		0.15	0.14	0.17	-0.47	0.37	0.57	0.46	0.47	0.26	-0.29	-0.29
Total Revenue	0.97	0.43	0.99	0.98	-0.56	-0.55	0.96	-0.5	0.96	-0.55	0.28	-0.55	0.15		1.0	1.0	-0.43	0.15	0.69	0.71	0.72	0.89	-0.57	-0.57
Gross Profit	0.96	0.4	0.98	0.97	-0.52	-0.5	0.94	-0.45	0.95	-0.5	0.26	-0.51	0.14	1.0		0.99	-0.38	0.14	0.67	0.68	0.7	0.88	-0.55	-0.55
Cost Of Revenue	0.98	0.45	0.99	0.99	-0.61	-0.6	0.97	-0.54	0.98	-0.59	0.29	-0.59	0.17	1.0	0.99		-0.47	0.16	0.72	0.74	0.75	0.89	-0.6	-0.6
Net Income From Continuing Ops	-0.51	-0.41	-0.54	-0.57	0.93	0.94	-0.66	0.95	-0.63	0.95	-0.26	0.95	-0.47	-0.43	-0.38	-0.47		-0.07	-0.79	-0.86	-0.78	-0.48	0.58	0.58
Non Operating Income Net Other	0.15	-0.25	0.18	0.19	-0.27	-0.28	0.23	-0.28	0.21	-0.01	0.97	-0.01	0.37	0.15	0.14	0.16	-0.07		0.36	0.3	0.33	0.3	-0.19	-0.19
Tax Provision	0.72	0.15	0.77	0.78	-0.84	-0.84	0.84	-0.83	0.82	-0.78	0.51	-0.79	0.57	0.69	0.67	0.72	-0.79	0.36		0.87	0.91	0.69	-0.67	-0.67
Interest Income	0.75	0.35	0.79	0.82	-0.92	-0.9	0.88	-0.88	0.86	-0.85	0.49	-0.85	0.46	0.71	0.68	0.74	-0.86	0.3	0.87		0.95	0.7	-0.79	-0.79
Net Interest Income	0.73	0.16	0.8	0.81	-0.86	-0.84	0.86	-0.82	0.85	-0.78	0.5	-0.79	0.47	0.72	0.7	0.75	-0.78	0.33	0.91	0.95		0.66	-0.72	-0.72
Reconciled Depreciation	0.88	0.48	0.88	0.89	-0.6	-0.59	0.89	-0.54	0.88	-0.54	0.42	-0.55	0.26	0.89	0.88	0.89	-0.48	0.3	0.69	0.7	0.66		-0.39	-0.39
Extraordinary Items	-0.63	-0.21	-0.65	-0.66	0.64	0.61	-0.7	0.6	-0.7	0.59	-0.33	0.59	-0.29	-0.57	-0.55	-0.6	0.58	-0.19	-0.67	-0.79	-0.72	-0.39		1.0
Non Recurring	-0.63	-0.21	-0.65	-0.66	0.64	0.61	-0.7	0.6	-0.7	0.59	-0.33	0.59	-0.29	-0.57	-0.55	-0.6	0.58	-0.19	-0.67	-0.79	-0.72	-0.39	1.0

Click cells to compare fundamentals

Tandem Diabetes Account Relationship Matchups

Tandem Diabetes income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Depreciation And Amortization	10.5M	13.8M	14.3M	15.7M	18.1M	19.0M
Interest Expense	78K	12.2M	4.3M	9.9M	11.4M	6.0M
Selling General Administrative	204.9M	261.5M	335.7M	352.5M	405.4M	425.6M
Other Operating Expenses	506.8M	680.1M	863.0M	980.9M	1.1B	1.2B
Operating Income	(8.0M)	8.8M	(61.8M)	(233.2M)	(209.9M)	(199.4M)
Ebit	(8.0M)	22.7M	(86.6M)	(210.4M)	(189.3M)	(179.9M)
Research Development	63.6M	92.1M	139.1M	169.7M	195.1M	204.9M
Ebitda	2.5M	36.5M	(72.3M)	(194.7M)	(175.2M)	(166.4M)
Total Operating Expenses	268.5M	353.6M	474.8M	600.9M	691.1M	725.6M
Income Before Tax	(36.3M)	15.9M	(92.9M)	(220.3M)	(198.2M)	(188.3M)
Total Other Income Expense Net	(28.3M)	(6.8M)	(4K)	13.0M	11.7M	12.3M
Net Income	(34.4M)	15.6M	(94.6M)	(222.6M)	(200.3M)	(190.3M)
Income Tax Expense	(1.9M)	335K	1.7M	2.4M	2.1M	2.2M
Total Revenue	498.8M	702.8M	801.2M	747.7M	859.9M	902.9M
Gross Profit	260.5M	376.2M	413.0M	367.7M	422.8M	444.0M
Cost Of Revenue	238.3M	326.6M	388.2M	380.0M	437.0M	458.9M
Net Income From Continuing Ops	(34.4M)	15.6M	(94.6M)	(222.6M)	(200.3M)	(190.3M)
Non Operating Income Net Other	(7.9M)	(28.3M)	(6.8M)	(4K)	(3.6K)	(3.8K)
Net Income Applicable To Common Shares	(24.8M)	(34.4M)	15.6M	(94.6M)	(108.8M)	(114.2M)
Tax Provision	(1.9M)	335K	1.7M	2.4M	2.7M	2.8M
Interest Income	1.6M	674K	6.1M	22.9M	26.3M	27.6M
Net Interest Income	(11.2M)	(5.4M)	(152K)	13.0M	14.9M	15.7M
Reconciled Depreciation	10.5M	13.8M	14.3M	15.7M	18.1M	11.5M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:

How To Invest In Tandem

Details

Is Tandem Stock a good investment?

Details

What is Tandem Diabetes' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.37)

Earnings Share

(1.94)

Revenue Per Share

13.082

Quarterly Revenue Growth

0.314

Return On Assets

(0.1)

The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tandem Historical Income Statement

About Tandem Income Statement Analysis

Tandem Diabetes Income Statement Chart

Other Operating Expenses

Operating Income

Total Operating Expenses

Tandem Diabetes income statement Correlations

Tandem Diabetes Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tandem Diabetes income statement Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Operating Expenses	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit
Total Operating Expenses	+ 1.0	Research Development
Net Income	+ 1.0	Income Before Tax
Gross Profit	+ 1.0	Total Revenue

Interest Income	- 0.92	Operating Income
Interest Income	- 0.9	Ebit
Interest Income	- 0.88	Ebitda
Interest Income	- 0.86	Net Income From Continuing Ops
Net Interest Income	- 0.86	Operating Income
Interest Income	- 0.85	Net Income